Genetic Signatures

39 Consolidated Statement of Cash Flows CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021 20 Consolidated Note 2021 2020 $’000s $’000s Cash flows from operating activities Receipts from customers (inclusive of GST) 30,031 8,882 Payments to suppliers and employees inclusive of GST) (28,680) (20,619) Interest and other income received 326 129 Lease costs (interest) 12 (36) (33) Research and development concession received 2,554 2,147 Net cash provided by/(used in) operating activities 25(b) 4,195 (9,494) Cash flows from investing activities Purchase of plant and equipment 11 (4,653) (2,275) Purchase of intangible assets (326) (75) Net cash used in investing activities (4,979) (2,350) Cash flows from financing activities Proceeds from issue of shares, net of costs 15 - 37,500 Proceeds from conversion of employee share ownership plan restricted shares 15 - 1,234 Proceeds from exercise of options 15 163 143 Share issue costs 15 (12) (1,892) Lease costs (principal) (341) (299) Net cash (used in)/provided by financing activities (190) 36,686 Net (decrease)/increase in cash and cash equivalents (974) 24,842 Cash and cash equivalents at beginning of financial year 31,176 6,312 Exchange differences on cash and cash equivalents (81) 22 Cash and equivalents at end of financial year 25(a) 30,121 31,176 The above consolidated statement of cash flows should be read in conjunction with the accompanying notes